Senior Security Analyst, Aignostics
AI-powered precision diagnostics for pathology
Job no longer available
AI-powered precision diagnostics for pathology
101-200 employees
Job no longer available
101-200 employees
Company mission
To power the next generation of precision medicine and advance the fields of AI and pathology.
Jump to section
Company mission
To power the next generation of precision medicine and advance the fields of AI and pathology.
Our take
There has been a worldwide increase in the numbers and complexity of cancer cases, alongside a predicted global shortage of pathologists. With this, classic manual analysis does not have the capability to support the precision medicine and drug development processes of the future.
Through its precision diagnostics platform, Aignostics turns complex biomedical data into transformative insights. It is able to power target identification (for drug development) and biomarker analyses, as well as support clinical trials with its toolkits.
The company is expanding its platform and reach, with initiatives like its Research Access Program driving adoption within the academic community. By offering free access to its spatial analysis tools, Aignostics is strengthening its data assets, validation base, and relationships with key opinion leaders. Alongside its US expansion and collaboration with the Mayo Clinic, these efforts support its long-term growth across research and biopharma applications.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 4 rounds)
Oct 2024
$34m
SERIES B
Sep 2022
$16.4m
SERIES A
Total funding: $57m
Leadership
Viktor Matyas
(Co-Founder & CEO)Prior to co-founding Aignostics in 2019, Viktor was a Senior Associate at Bridgepoint for 3 years.
Maximilian Alber
(Co-Founder & CTO)Maximilian was previously a Researcher at the Berlin Institute of Technology for 4 years.